© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
Data from a phase III study have linked the advanced prostate cancer drug abiraterone acetate (ZYTIGA) to delayed pain progression and functional decline in a certain subset of advanced prostate cancer patients.